Eli Lilly was among the investors in neurodegenerative disease drug developer Vanqua Bio’s $85m series B round.

Vanqua Bio, a US-based developer of treatments for neurodegenerative diseases, emerged from stealth yesterday with $85m in series B funding from investors including pharmaceutical firm Eli Lilly. Omega Funds led the round, which also featured OrbiMed, Surveyor Capital, Avoro Ventures, Casdin Capital, Pontifax, Osage University Partners and Logos Capital. Founded in 2019 as Surmount Bio,…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.